CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas.
SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
大B细胞淋巴瘤（LBCL）是一种异质性疾病，以蒽环类药物为基础的化学免疫治疗可治愈大多数患者。然而，仍有相当一部分患者出现难治性疾病或复发，且预后仍然不佳。因此，提高一线治愈率仍然是淋巴瘤领域的一个基本目标，并促使了多种治疗策略的开发。在此，我们讨论旨在超越标准化疗改善结局的方法，并探讨LBCL中4个具有变革性的问题：（1）免疫治疗能否提高一线治愈率；（2）精准医学是否是克服遗传异质性的合理方法；（3）LBCL能否在不使用化疗的情况下被治愈；（4）循环肿瘤DNA（ctDNA）能否在反应适应性策略中辅助临床决策。总之，这些方法反映了不断演变的策略，可能改善一线结局，并为LBCL患者未来的治疗范式提供信息。
Large B-cell lymphoma (LBCL) is a heterogeneous disease for which anthracycline-based chemoimmunotherapy cures most patients.
However, a substantial minority of patients experience refractory disease or relapse, and outcomes remain poor. Improving frontline cure rates therefore remains a fundamental objective in the lymphoma field and has led to the development of multiple therapeutic strategies.
Herein, we discuss approaches aimed at improving outcomes beyond standard chemotherapy and address 4 transformative questions in LBCL: (1) can immunotherapy improve frontline cure rates; (2) is precision medicine a sound approach to overcome genetic heterogeneity; (3) can LBCL be cured without chemotherapy; (4) can circulating tumor DNA (ctDNA) aid clinical decision-making in response-adapted strategies.
Together, these approaches reflect evolving strategies that may improve frontline outcomes and inform future treatment paradigms for patients with LBCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
